HOOKIPA Pharma Inc. - HOOK STOCK NEWS

Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.

HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.

VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.

HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.

In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.

As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.

03/06/2024 07:01 AM

News

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Rhea-AI Summary

HOOKIPA Pharma Inc. (HOOK) CFO to present at Leerink Partners Global Biopharma Conference 2024. The company focuses on immunotherapeutics using its proprietary arenavirus platform.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.38%

Tags

01/29/2024 08:01 AM

News

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Rhea-AI Summary

HOOKIPA Pharma Inc. announced strategic priorities to focus on advancing clinical programs for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. The company will prioritize the clinical development of a randomized trial for HB-200 in HPV16+ head and neck squamous cell carcinoma, implement cost-saving initiatives, and reduce its workforce by 30 percent. HOOKIPA will also regain global development rights to HB-700 program for KRAS-mutated cancers from Roche and maintain a strong cash position of $117.5 million as of December 31, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.13%

Tags

01/16/2024 07:01 AM

News

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Rhea-AI Summary

HOOKIPA Pharma Inc. appoints Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024. Dr. Winderlich brings extensive experience in leading drug development processes and will focus on advancing the HB-200 program to improve the standard of care for people with advanced HPV16+ head and neck cancer. He joins HOOKIPA from Evotec SE, where he led the partnership with Bristol Myers Squibb in oncology and played key roles in the development of multiple drug candidates. Dr. Winderlich's appointment reflects HOOKIPA's commitment to advancing novel arenaviral therapies for cancer and infectious diseases.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-9.15%

Tags

12/21/2023 07:01 AM

News

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced that Gilead Sciences has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share. Following the transaction, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock. The equity investment aims to advance the Gilead-partnered HIV therapeutic program through Phase 1, with the trial expected to commence in the first half of 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

52.74%

Tags

11/20/2023 07:01 AM

News

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) has received FDA clearance for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. The Phase 1 trial will commence in the first half of 2024, following the publication of peer-reviewed preclinical data in Nature Partner Journals (NPJ) Vaccines. The vaccine has shown safety, immunogenicity, and efficacy in preclinical testing, and Gilead Sciences, Inc. has the exclusive right to assume further development of the program after HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.31%

Tags

11/09/2023 07:01 AM

News

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported positive preliminary Phase 2 data for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer. The data reinforce strong objective response rate and disease control rate reported in Q2 2023. The company also published peer-reviewed preclinical data for HB-400 program in The Journal of Infectious Disease. Recruitment is ongoing for two Phase 1 clinical trials for advanced prostate cancer and chronic hepatitis B. IND-enabling activities are in progress to advance two additional therapeutic candidates into the clinic in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-12%

Tags

11/03/2023 12:01 PM

News

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Rhea-AI Summary

HOOKIPA Pharma Inc. announced updated Phase 1 clinical data on HB-200 as a monotherapy in patients with recurrent/metastatic HPV16+ head and neck cancer. The data show that HB-200 induced robust tumor-specific T cell responses, with a 44 percent disease control rate in a difficult-to-treat patient population.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.21%

Tags

11/02/2023 04:01 PM

News

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its third quarter 2023 financial results and business highlights on November 9, 2023. No conference call will be conducted.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.21%

Tags

10/22/2023 06:01 AM

News

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Rhea-AI Summary

HOOKIPA Pharma presents updated data from Phase 2 trial of HB-200 in combination with pembrolizumab for head and neck cancer

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/18/2023 07:01 AM

News

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Rhea-AI Summary

HOOKIPA Pharma announces publication of preclinical data on HB-400, a potential therapeutic vaccine for chronic hepatitis B

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.15%

Tags

FAQ

What is the current stock price of HOOKIPA Pharma (HOOK)?

The current stock price of HOOKIPA Pharma (HOOK) is $2.3 as of November 21, 2024.

What is the market cap of HOOKIPA Pharma (HOOK)?

The market cap of HOOKIPA Pharma (HOOK) is approximately 30.4M.

What does HOOKIPA Pharma Inc. specialize in?

HOOKIPA Pharma Inc. specializes in developing immunotherapeutics targeting infectious diseases and cancer using its proprietary arenavirus platform.

What are VaxWave® and TheraT®?

VaxWave® and TheraT® are proprietary technologies developed by HOOKIPA to stimulate the immune system. VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector.

How do the arenavirus technologies work?

The technologies reprogram the immune system to induce pathogen-neutralizing antibodies and CD8+ T cells, effectively targeting and neutralizing infectious agents and cancer cells.

What recent achievements has HOOKIPA made?

HOOKIPA has successfully completed a Phase 1 clinical trial and is advancing its pipeline with new immunotherapies for HPV16-positive oropharyngeal cancer and KRAS mutant cancer.

How are HOOKIPA's viral vectors administered?

HOOKIPA's viral vectors are administered systemically, targeting dendritic cells in vivo and activating the immune system to combat diseases.

What is the financial condition of the company?

As of December 31, 2023, HOOKIPA maintains a strong financial position, supporting its ongoing research and development efforts.

What is the significance of TheraT® in cancer treatment?

TheraT® induces CD8+ T cell responses to tumor antigens, achieving frequencies and potencies that match or exceed those observed in adoptive T cell therapy, making it significant for cancer treatment.

Who can be contacted for investor relations?

For investor relations, Michael Kaiser can be contacted at michael.kaiser@hookipapharma.com or +1 (917) 984 7537.

What are the upcoming projects for HOOKIPA?

Upcoming projects include the continued development of arenavirus-based immunotherapies for various cancers, including KRAS mutant cancer and HPV16-positive oropharyngeal cancer.

What makes HOOKIPA's technologies unique?

HOOKIPA's technologies are unique because they allow repeated administration while maintaining efficacy, and they target dendritic cells to activate the immune system effectively.